In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial
Background: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties. Aims: We evaluated the plasma level of some cyt...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2015-12-01
|
| Series: | Balkan Medical Journal |
| Subjects: | |
| Online Access: | http://balkanmedicaljournal.org/text.php?lang=en&id=183 |
| _version_ | 1797918505375367168 |
|---|---|
| author | Corina I. Bocşan Ştefan C. Vesa Adriana I. Bujor Nicolae Miron Diana Deleanu Anca D. Buzoianu |
| author_facet | Corina I. Bocşan Ştefan C. Vesa Adriana I. Bujor Nicolae Miron Diana Deleanu Anca D. Buzoianu |
| author_sort | Corina I. Bocşan |
| collection | DOAJ |
| description | Background: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties.
Aims: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 antihistamines, as well as the risk of asthma after 1.5 years.
Study Design: Randomized clinical trial.
Methods: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients under 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and total symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1β, IL-6, IL-8 and TNF-α.
Results: IL-8 and TNF-α were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p<0.001 and 2.32 vs 1.06, p<0.001, respectively). Both H1 antihistamines reduce all symptoms of allergic rhinitis, including nasal congestion and the plasmatic level of IL-1β, IL-6, IL-8 and TNF-α, after 4 weeks of treatment. The reduction of cytokine levels was not influenced by patients’ age, sex, duration or severity of rhinitis, or type of sensitization. Levocetirizine has a superior effect compared to desloratadine in reducing the rhinitis symptoms and cytokines’ level. Twenty eight (32.9%) of the patients presented asthma symptoms after 1.5 years. The occurrence of asthma was influenced by house dust sensitization (OR-14.6; CI 95% 1.8-116.3; p=0.01), but baseline values of cytokines were not predictive factors for its appearance.
Conclusion: Levocetirizine and desloratadine as a prolonged therapy reduce plasmatic levels of some pro-inflammatory cytokines in patients with PAR. Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1β and IL-8. (ClinicalTrials.gov Identifier: NCT02507635) |
| first_indexed | 2024-04-10T13:30:17Z |
| format | Article |
| id | doaj.art-97ab39950edd4ac1a2b7a63f58aa5c4c |
| institution | Directory Open Access Journal |
| issn | 2146-3123 2146-3131 |
| language | English |
| last_indexed | 2024-04-10T13:30:17Z |
| publishDate | 2015-12-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Balkan Medical Journal |
| spelling | doaj.art-97ab39950edd4ac1a2b7a63f58aa5c4c2023-02-15T16:11:40ZengGalenos Publishing HouseBalkan Medical Journal2146-31232146-31312015-12-0132435235810.5152/balkanmedj.2015.15884In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical TrialCorina I. Bocşan0Ştefan C. Vesa1Adriana I. Bujor2Nicolae Miron3Diana Deleanu4Anca D. Buzoianu5Department of Clinical Pharmacology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaDepartment of Clinical Pharmacology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaDepartment of Allergology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaDepartment of Allergology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaDepartment of Allergology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaDepartment of Allergology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaBackground: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties. Aims: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 antihistamines, as well as the risk of asthma after 1.5 years. Study Design: Randomized clinical trial. Methods: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients under 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and total symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1β, IL-6, IL-8 and TNF-α. Results: IL-8 and TNF-α were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p<0.001 and 2.32 vs 1.06, p<0.001, respectively). Both H1 antihistamines reduce all symptoms of allergic rhinitis, including nasal congestion and the plasmatic level of IL-1β, IL-6, IL-8 and TNF-α, after 4 weeks of treatment. The reduction of cytokine levels was not influenced by patients’ age, sex, duration or severity of rhinitis, or type of sensitization. Levocetirizine has a superior effect compared to desloratadine in reducing the rhinitis symptoms and cytokines’ level. Twenty eight (32.9%) of the patients presented asthma symptoms after 1.5 years. The occurrence of asthma was influenced by house dust sensitization (OR-14.6; CI 95% 1.8-116.3; p=0.01), but baseline values of cytokines were not predictive factors for its appearance. Conclusion: Levocetirizine and desloratadine as a prolonged therapy reduce plasmatic levels of some pro-inflammatory cytokines in patients with PAR. Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1β and IL-8. (ClinicalTrials.gov Identifier: NCT02507635)http://balkanmedicaljournal.org/text.php?lang=en&id=183Cytokineshistamine H1 antagonistsallergic rhinitis |
| spellingShingle | Corina I. Bocşan Ştefan C. Vesa Adriana I. Bujor Nicolae Miron Diana Deleanu Anca D. Buzoianu In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial Balkan Medical Journal Cytokines histamine H1 antagonists allergic rhinitis |
| title | In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial |
| title_full | In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial |
| title_fullStr | In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial |
| title_full_unstemmed | In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial |
| title_short | In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial |
| title_sort | in vivo anti inflammatory effect of h1 antihistamines in allergic rhinitis a randomized clinical trial |
| topic | Cytokines histamine H1 antagonists allergic rhinitis |
| url | http://balkanmedicaljournal.org/text.php?lang=en&id=183 |
| work_keys_str_mv | AT corinaibocsan invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial AT stefancvesa invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial AT adrianaibujor invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial AT nicolaemiron invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial AT dianadeleanu invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial AT ancadbuzoianu invivoantiinflammatoryeffectofh1antihistaminesinallergicrhinitisarandomizedclinicaltrial |